Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives.

IF 1.9 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiology Pub Date : 2024-01-01 Epub Date: 2024-02-14 DOI:10.1159/000537706

Archana Kulasingam, Manan Pareek, Felice Gragnano, Morten Würtz, Kasper Pryds, Paolo Calabrò, Erik Lerkevang Grove

{"title":"Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives.","authors":"Archana Kulasingam, Manan Pareek, Felice Gragnano, Morten Würtz, Kasper Pryds, Paolo Calabrò, Erik Lerkevang Grove","doi":"10.1159/000537706","DOIUrl":null,"url":null,"abstract":"Background: The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential.Summary: Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with, e.g., concomitant atrial fibrillation or venous thromboembolism.Key messages: This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"502-512"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000537706","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential.

Summary: Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with, e.g., concomitant atrial fibrillation or venous thromboembolism.

Key messages: This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.

查看原文本刊更多论文

慢性冠状动脉综合征的抗血栓治疗：证据与未来展望。

背景冠状动脉疾病的临床表现可从无症状到慢性冠状动脉综合征形式的稳定疾病，再到急性冠状动脉综合征。慢性冠状动脉综合征是一种常见病，缺血性事件的二级预防至关重要。摘要抗血栓治疗是二级预防策略的关键组成部分，其类型和强度可能因患者特征、合并症和血管再通方式而异。双联抗血小板疗法是慢性冠状动脉综合征和近期冠状动脉支架植入患者的默认策略，而单联抗血小板疗法则是长期预防心血管事件的常用处方。口服抗凝药与抗血小板疗法联合或单独用于合并心房颤动或静脉血栓栓塞等疾病的患者。关键信息本综述概述了慢性冠状动脉综合征患者的抗血栓治疗策略。我们传达了现行指南的关键信息，并对长期抗血栓策略提出了未来展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiology 医学-心血管系统

CiteScore

3.40

自引率

5.30%

发文量

审稿时长

1.5 months

期刊介绍： ''Cardiology'' features first reports on original clinical, preclinical and fundamental research as well as ''Novel Insights from Clinical Experience'' and topical comprehensive reviews in selected areas of cardiovascular disease. ''Editorial Comments'' provide a critical but positive evaluation of a recent article. Papers not only describe but offer critical appraisals of new developments in non-invasive and invasive diagnostic methods and in pharmacologic, nutritional and mechanical/surgical therapies. Readers are thus kept informed of current strategies in the prevention, recognition and treatment of heart disease. Special sections in a variety of subspecialty areas reinforce the journal''s value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons, clinical physiologists, pharmacologists and professionals in other areas of medicine interested in current activity in cardiovascular diseases.